Clinical Trial Update: Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation [Phase 1]

View source ↗

Summary

Phase 1 safety study of IDH1/IDH2 inhibitors AG-120 (ivosidenib) or AG-221 (enasidenib) combined with induction and consolidation therapy for newly diagnosed, u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AG-120 (ivosidenib)
• AG-221 (enasidenib)

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML | Phase 1 | Status: ACTIVE_NOT_RECRUITING